Human papillomavirus: opportunities and challenges for us.
Chinese Journal of Experimental and Clinical Virology.2009;23(2):81-81.
Chinese Journal of Experimental and Clinical Virology
1987 to Present ISSN: 1003-9279
Sort by
DISPLAY OPTIONS
Format:
Per page:
Great success achieved in hepatitis contral and prevention.
Chinese Journal of Experimental and Clinical Virology.2009;23(1):1-1.
The establishment and running status of Chinese measles laboratory anetwork.
Chinese Journal of Experimental and Clinical Virology.2008;22(6):401-402.
Research in arbovirus should be strengthened in China.
Chinese Journal of Experimental and Clinical Virology.2005;19(4):305-306.
Antiviral therapy of chronic hepatitis B patients resistant to lamivudine.
Chinese Journal of Experimental and Clinical Virology.2005;19(4):395-397.
BACKGROUNDTo evaluate the efficacy of alpha-2b interferon alone or combined with alpha1-thymosin in treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine.
METHODSSixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A, treatment group B and control group. In the treatment group A 26 cases, after giving interferon-alpha alone for 1 month, lamivudine was withdrawn and continuously treated with interferon-alpha for 5 months. In the treatment group B 10 cases, after treatment with interferon-alpha and thymosin-alpha1 for 1 month, lamivudine was withdrawn and continuously treated with interferon-alpha and thymosin-alpha1 for 5 months. In control group (30 cases), after lamivudine was directly withdrawn, no anti-virus drug was given. Hepatic function tests and serum virological index were detected at regular intervals in all patients.
RESULTSNormalization rate of hepatic function, HBV DNA seroconversion rate and HBeAg/HBeAb seroconversion rate in two treatment groups were significantly higher than those in control group.
CONCLUSIONThe study suggested that interferon-alpha alone or combined with thymosin-alpha1 in treatment of patients with chronic hepatitis B resistant to lamivudine showed a beneficial effect.
Adolescent ; Adult ; Antiviral Agents ; therapeutic use ; DNA, Viral ; blood ; genetics ; Drug Resistance, Viral ; Drug Therapy, Combination ; Female ; Hepatitis B Antibodies ; blood ; Hepatitis B e Antigens ; immunology ; Hepatitis B virus ; drug effects ; genetics ; immunology ; Hepatitis B, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; therapeutic use ; Lamivudine ; pharmacology ; therapeutic use ; Male ; Middle Aged ; Recombinant Proteins ; Thymosin ; therapeutic use ; Treatment Outcome
Dynamic expression of hepatitis B virus covalently closed circular DNA in 2.2.15 cell.
Chinese Journal of Experimental and Clinical Virology.2005;19(4):391-394.
BACKGROUNDTo determine the presence of covalently closed circular DNA (cccDNA), and to investigate the expression kinetics of HBV DNA, HBsAg and HBeAg in 2.2.15 cell.
METHODSHBV cccDNA was assessed by polymerase chain reaction, HBV DNA was measured by Taqman quantitative PCR and HBsAg and HBeAg was measured by EIA.
RESULTSHBV cccDNA was found in both intracellular and extracellular space. There was a good correlation between HBsAg, HBeAg and HBV DNA in the supernatant of 2.2.15 cell (r= 0.833, P < 0.05 and r= 0.939, P < 0.01 for HBsAg and HBeAg, respectively), whereas there was no significant correlation between intracellular HBV DNA levels and virus antigen levels (r= 0.024, P= 0.955 and r= 0.177; P= 0.625 for HBsAg and HBeAg, respectively).
CONCLUSIONHBV cccDNA was detectable in the culture medium and intracellularly in 2.2.15 cells, and these data provided an indication of HBV replication in 2.2.15 cell.
Cell Line, Tumor ; DNA, Circular ; genetics ; DNA, Viral ; chemistry ; genetics ; Hepatitis B Surface Antigens ; analysis ; Hepatitis B e Antigens ; analysis ; Hepatitis B virus ; genetics ; immunology ; Humans ; Polymerase Chain Reaction ; methods ; Sequence Analysis, DNA
Chinese Journal of Experimental and Clinical Virology.2005;19(4):387-390.
BACKGROUNDTo investigate the frequency of circulating HBV specific T helper cell and evaluate its association with serum levels of HBV DNA before and during lamivudine treatment in patients with chronic hepatitis B.
METHODSThe frequency of circulating HBV specific T helper cells in response to HBcAg in 25 chronic HBV-infected patients was determined by Elispot assay; serum HBV DNA was quantitated by real-time PCR.
RESULTSThe frequency of HBV specific T helper cell before antiviral treatment (47.30 +/- 25.50 SFCs /1 x 10(6) PBMC) was significantly higher than that at the third month of therapy (23.10 +/- 18.45 SFCs /1 x 10(6) PBMC, P < 0.05). All 8 patients observed dynamically had decreased frequency of HBV specific T helper cell at the third month of therapy; six patients with serum HBV DNA level reduced had higher frequency of HBV specific T helper cell before treatment than 2 patients without serum HBV DNA level decrease.
CONCLUSIONHBV specific T helper cell response at the time of hepatitis flare in chronic hepatitis B patients was significantly augmented compared to that at the time of catabasis.
Adult ; Antiviral Agents ; therapeutic use ; DNA, Viral ; blood ; genetics ; Enzyme-Linked Immunosorbent Assay ; methods ; Female ; Hepatitis B Core Antigens ; immunology ; Hepatitis B virus ; drug effects ; genetics ; immunology ; Hepatitis B, Chronic ; blood ; drug therapy ; virology ; Humans ; Lamivudine ; therapeutic use ; Male ; T-Lymphocytes, Helper-Inducer ; cytology ; drug effects ; immunology
A clinical study on CD178 positive T lymphocyte in hemorrhagic fever with renal syndrome.
Chinese Journal of Experimental and Clinical Virology.2005;19(4):383-386.
BACKGROUNDTo further probe into the role of CD178 in the pathogenesis of hemorrhagic fever with renal syndrome (HFRS).
METHODSThe expression of CD178 and HLA-DR on T cell subsets in peripheral blood of patients with HFRS and their dynamic changes were detected by Flow cytometry.
RESULTSCD4+ CD178+ and CD8+ CD178+ T lymphocytes both in fever and polyuria phases were significantly higher than those in normal controls, while there was no significant difference between the both phases of HFRS (P > 0.05). CD178 expression on CD4+ HLA-DR+ and CD8+ HLA-DR+ T lymphocytes were significantly higher than those in normal controls (P < 0.05, P < 0.01, P < 0.001, P < 0.001), while there was no significant difference between CD4+ HLA-DR+ and CD8+ HLA-DR+ T lymphocytes (P > 0.05).
CONCLUSIONCD178 was expressed on both CD4+ and CD8+ T cell subsets, but mainly on CD8+ T cell subsets both in early stage and in later stage in the pathogenesis of HFRS. Cytotoxic T lymphocyte (CTL) might kill target cells infected by hantavirus (HV) and eliminate HV via cell apoptosis mediated by CD178 in early stage of HFRS. In later stage of HFRS, CD178 might reduce antigen-specific T lymphocytes by activation induced cell death (AICD) and help to maintain the homeostasis of immune system.
Adolescent ; Adult ; CD4-Positive T-Lymphocytes ; cytology ; immunology ; CD8-Positive T-Lymphocytes ; cytology ; immunology ; Fas Ligand Protein ; immunology ; Female ; Flow Cytometry ; Hemorrhagic Fever with Renal Syndrome ; blood ; immunology ; Hemorrhagic Fevers, Viral ; blood ; immunology ; Humans ; Male ; Middle Aged ; T-Lymphocyte Subsets ; cytology ; immunology ; Young Adult
Chinese Journal of Experimental and Clinical Virology.2005;19(4):380-382.
BACKGROUNDTo evaluate treatment effectiveness and safety of bicyclo tablets in children with chronic hepatitis B or C.
METHODSA randomized controlled trial was conducted in 148 children with chronic hepatitis B or C for evaluating safety, tolerability, and efficacy of treatment with bicyclo tablets or Hugan tablets. Children in therapy group were treated with bicyclo tablets and control group treated with Hugan tablets.
RESULTS(1) ALT and AST level decreased more prominently in therapy group than in control group (P<0.01). (2) Bicyclo was more effective than Hugan tablets (P<0.01). (3) Symptoms were ameliorated more prominently in bicyclo group than in control group (P<0.01). (4) Both groups had no significant adverse events.
CONCLUSIONSatisfactory therapeutic effect and safety were obtained with bicyclo tablets in children with chronic hepatitis B or C.
Adolescent ; Biphenyl Compounds ; adverse effects ; therapeutic use ; Child ; Child, Preschool ; Hepatitis B, Chronic ; drug therapy ; Hepatitis C, Chronic ; drug therapy ; Humans ; Tablets ; Treatment Outcome
Safety and tolerance study of single oral dose of adefovir dipivoxil tablets in healthy volunteers.
Chinese Journal of Experimental and Clinical Virology.2005;19(4):375-379.
BACKGROUNDTo assess the safety and tolerance of adefovir dipivoxil tablet in Chinese healthy volunteers.
METHODSTotally 42 healthy volunteers were enrolled in the study, 21 were female and 21 were male and their age ranged from 19 to 26 years. The subjects were randomly divided into 5, 10, 20, 40 and 60 mg dose-groups (6-10 subjects in each group) based on sex and weight, beginning with the 5 mg dose-group. Clinical symptoms, vital signs, electrocardiogram, routine blood test, routine urine test, prothrombin time and blood biochemical tests were recorded and evaluated.
RESULTSNo significant changes were found in clinical symptoms, vital signs and laboratory tests after dosing, except slight elevations of alanine aminotransferase in 2 subjects and bilirubin in 6 subjects observed and some gastrointestinal symptoms such as nausea and diarrhea found in 3 subjects, but the frequency and severity of all the adverse reactions were not found to be related to the dosages.
CONCLUSIONThe results showed that single oral dose of adefovir dipivoxil 60 mg or less was safe and tolerable.
Adenine ; administration & dosage ; adverse effects ; analogs & derivatives ; Administration, Oral ; Adult ; Antiviral Agents ; administration & dosage ; adverse effects ; Diarrhea ; chemically induced ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Nausea ; chemically induced ; Organophosphonates ; administration & dosage ; adverse effects ; Tablets ; Young Adult
Country
China
Publisher
中华医学会
ElectronicLinks
https://zhsyhlcbdxzz.yiigle.com/Editor-in-chief
hungt@public3.btas.net.cn
Abbreviation
Chinese Journal of Experimental and Clinical Virology
Vernacular Journal Title
中华实验和临床病毒学杂志
ISSN
1003-9279
EISSN
Year Approved
2007
Current Indexing Status
Currently Indexed
Start Year
1987
Description
历史沿革【现用刊名：中华实验和临床病毒学杂志;曾用刊名：实验和临床病毒学杂志;创刊时间：1987】，该刊被以下数据库收录【CA 化学文摘(美)(2009);CBST 科学技术文献速报(日)(2009);中国科学引文数据库(CSCD—2008)】，核心期刊【中文核心期刊(2008);中文核心期刊(2004);中文核心期刊(2000)】，期刊荣誉【中科双效期刊】。
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)